Extended LTA, TNF, LST1 and hla gene haplotypes and their association with rubella vaccine-induced immunity

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Ovsyannikova, Inna G ^a   Vierkant, Robert A ^a   Pankratz, V Shane ^a   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DQA1 ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 6; LEUKOCYTE SPECIFIC TRANSCRIPT 1; LYMPHOTOXIN; MEASLES MUMPS RUBELLA VACCINE; RUBELLA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; HLA DQ ANTIGEN; HLA-DRB1 ANTIGEN; LST1 PROTEIN, HUMAN; MEMBRANE PROTEIN; RUBELLA VACCINE;

ADOLESCENT; ADULT; ALLELE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CHILD; CHROMOSOME 6P; CYTOKINE RELEASE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNITY; MALE; NORMAL HUMAN; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION; GENETICS; GENOTYPE; IMMUNOLOGY;

RUBELLA;

ADOLESCENT; ADULT; CHILD; FEMALE; GENOTYPE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; LYMPHOTOXIN-ALPHA; MALE; MEMBRANE PROTEINS; RUBELLA VACCINE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77955616913     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011806     Document Type: Article

References (32)

1. Ovsyannikova IG, Pankratz SV, Vierkant R, Jacobson RM, Poland GA (2006) Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J Infect Dis 193: 655-663.
2. Kimman TG, Vandebriel RJ, Hoebee B (2007) Genetic variation in the response to vaccination. Community Genet 10: 201-217.
3. Hennig BJ, Fielding K, Broxholme J, Diatta M, Mendy M, et al. (2008) Host genetic factors and vaccine-induced immunity to hepatitis B virus infection. PLoS ONE 3: e1898.
4. Ovsyannikova IG, Haralambieva IH, Dhiman N, O'Byrne MM, Pankratz VS, et al. (2010) Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis 201: 207-213.
5. Vejbaesya S, Luangtrakool P, Luangtrakool K, Kalayanarooj S, Vaughn DW, et al. (2009) TNF and LTA Gene, Allele, and Extended HLA Haplotype Associations with Severe Dengue Virus Infection in Ethnic Thais. J Infect Dis 199: 1442-1448.
6. Diakite M, Clark TG, Auburn S, Campino S, Fry AE, et al. (2009) A genetic association study in the Gambia using tagging polymorphisms in the major histocompatibility complex class III region implicates a HLA-B associated transcript 2 polymorphism in severe malaria susceptibility. Hum Genet 125: 105-109.
7. Hill AV (2001) The genomics and genetics of human infectious disease susceptibility. Annu Rev Genomics Hum Genet 2: 373-400.
8. Posch PE, Cruz I, Bradshaw D, Medhekar BA (2003) Novel polymorphisms and the definition of promoter 'alleles' of the tumor necrosis factor and lymphotoxin alpha loci: inclusion in HLA haplotypes. Genes Immun 4: 547-558.
9. Hohler T, Kruger A, Gerken G, Schneider PM, Meyer zum Buschenefelde KH, et al. (1998) A tumor necrosis factor-alpha (TNF-alpha) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol 111: 579-582.
10. Mewar D, Marinou I, Lee ME, Timms JM, Kilding R, et al. (2006) Haplotypespecific gene expression profiles in a telomeric major histocompatibility complex gene cluster and susceptibility to autoimmune diseases. Genes Immun 7: 625-631.
11. Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214: 149-160.
12. Lanas A, Garcia-Gonzalez MA, Santolaria S, Crusius JB, Serrano MT, et al. (2001) TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients. Genes Immun 2: 415-421.
13. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW (1997) Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 94: 3195-3199.
14. Kerr JR, McCoy M, Burke B, Mattey DL, Pravica V, et al. (2003) Cytokine gene polymorphisms associated with symptomatic parvovirus B19 infection. J Clin Pathol 56: 725-727.
15. Tomoyose T, Komiya I, Takara M, Yabiku K, Kinjo Y, et al. (2002) Cytotoxic T-lymphocyte antigen-4 gene polymorphisms and human T-cell lymphotrophic virus-1 infection: their associations with Hashimoto's thyroiditis in Japanese patients. Thyroid 12: 673-677.
16. Rau H, Usadel KH, Ommert S, Badenhoop K (1995) PVU II polymorphism of LST-1 (leucocyte specific transcript-1) in type I diabetes mellitus, Graves' disease and healthy controls. Eur J Immunogenet 22: 277-282.
17. Rollinger-Holzinger I, Eibl B, Pauly M, Griesser U, Hentges F, et al. (2000) LST1: a gene with extensive alternative splicing and immunomodulatory function. J Immunol 164: 3169-3176.
18. Mulcahy H, O'Rourke KP, Adams C, Molloy MG, O'Gara F (2006) LST1 and NCR3 expression in autoimmune inflammation and in response to IFN-gamma, LPS and microbial infection. Immunogenetics 57: 893-903.
19. Ovsyannikova IG, Vierkant RA, Pankratz VS, O'Byrne MM, Jacobson RM, et al. (2009) HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine. Vaccine 27: 3349-3358.
20. Ovsyannikova IG, Jacobson RM, Vierkant RA, O'Byrne MM, Poland GA (2009) Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine 27: 6926-6931.
21. Ovsyannikova IG, Ryan JE, Vierkant RA, O'Byrne MM, Jacobson RM, et al. (2009) Influence of host genetic variation on rubella-specific T cell cytokine responses following rubella vaccination. Vaccine 27: 3359-3366.
22. Yang Y, Sempé P, Peterson PA (1996) Molecular mechanisms of class I major histocompatibliity complex antigen processing and presentation. Immunol Res 15: 208-233.
23. Robinson JH, Delvig AA (2002) Diversity in MHC class II antigen presentation. Immunology 105: 252-262.
24. Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI (2007) Heterogeneity in vaccine immune response: The role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 82: 653-664.
25. Ou D, Mitchell LA, Ho M, Décarie D, Tingle AJ, et al. (1994) Analysis of overlapping T- and B-cell antigenic sites on rubella virus E1 envelope protein. Influence of HLA-DR4 polymorphism on T-cell clonal recognition. Hum Immunol 39: 177-187.
26. Ou D, Mitchell LA, Décarie D, Gillam S, Tingle AJ (1997) Characterization of an overlapping CD8+ and CD4+ T-cell epitope on rubella capsid protein. Virology 235: 286-292.
27. Nepom GT, Domeier ME, Ou D, Kovats S, Mitchell LA, et al. (1997) Recognition of contiguous allele-specific peptide elements in the rubella virus E1 envelope protein. Vaccine 15: 648-652.
28. Miretti MM, Walsh EC, Ke X, Delgado M, Griffiths M, et al. (2005) A highresolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms. Am J Hum Genet 76: 634-646.
29. Poland GA, Ovsyannikova IG, Jacobson RM (2008) Personalized vaccines: The emerging field of vaccinomics. Expert Opinion on Biological Therapy 8: 1659-1667.
30. Ovsyannikova IG, Jacobson RM, Vierkant RA, Jacobsen SJ, Pankratz VS, et al. (2004) The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol 65: 1506-1515.
31. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70: 425-434.
32. Nagelkerke NJD (1991) A note on a general definition of the coefficient of determination. Biometrika 78(3): 691-692.